Download MendeleySevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel, F., Siegel, S., Kotynkova, K., Karsli Uzunbas, G., Korr, D., Tomono, H., Andersen, S., Denney, D., Berger, M., Schulze, V.K., Lewis, T.A., Kaplan, B., Golfier, S., Mortier, J., Hillig, R.C., Boemer, U., Petersen, K., Eis, K., Williams, S., Ruttinger, D., Cherniack, A.D., Loong, H.H., Goto, K., Grassi, P., Meyerson, M., Greulich, H.(2025) Cancer Discov
- PubMed: 41090369
- DOI: https://doi.org/10.1158/2159-8290.CD-25-0605
- Primary Citation of Related Structures:
9QXN - PubMed Abstract:
Exon 20 insertions of HER2, encoded by ERBB2, and other activating HER2 mutations occur in 2-4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is a potent and reversible dual EGFR-HER2 inhibitor that is selective with respect to wild-type EGFR. Here, we report the preclinical activity of sevabertinib in lung cancer models harboring alterations of HER2, including exon 20 insertions, point mutations, and amplification of wild-type ERBB2. We furthermore demonstrate the activity of sevabertinib in a cancer cell line dependent on a fusion of NRG1, a ligand for the HER2 family member and heterodimerization partner, HER3. Finally, we report patient responses to sevabertinib from a Phase 1/2 clinical trial, indicating potential benefit for patients with HER2-mutant lung cancer.
- Bayer AG, Germany.
Organizational Affiliation:
